Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS) Continues Strong Series to 7 Cents

The market is always hungry for a good story from the biopharmaceutical sector, and now Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS) is vying for attention, after three unusually strong days. AMBS added more than 25% on Friday, climbing to 7 cents, on volumes above $2.33 million. AMBS0902.png

After a series of promotions and PR hype at the end of 2012, AMBS retreated, rarely showing up among the most actively traded penny stocks, until it bottomed out at 3 cents. And the recovery in the past month has been relatively rapid.ACTC0902.png

AMBS came in with two PR announcements on presenting its case to peer-reviewed journals, as well as investor conferences. Along with this, the company is nearer to receiving a desirable “orphan drug” status for one of its ophthalmology treatments. Added to this the lower price of past months, and AMBS becomes a new winning package.

AMBS has not been promoted since mid-June, when TITAN Stock Alerts played up the possibility that AMBS would create a treatment for Alzheimer’s disease. Now, with the new rise, a promoter could take up AMBS again and share the positive trend.

The latest financial results show that AMBS is equipped somehow to continue its attempts at delivering a sought-after treatment. AMBS holds:

  • $67,061 cash
  • $1.2 million total assets
  • $5.57 million total current liabilities NNVC0902.png
  • $900,985 quarterly net loss

$15.2 million net loss since inception
But the stock’s movement would now be untied from the underlying business, as pharmaceutical tickers tend to move based on sentiment.

Another long-time runner, Advanced Cell Technology, Inc. (OTCBB:ACTC) is currently struggling with a low, unable to provide enough comfort to investors. ACTC is traded in volumes above $510,000, and currently dropped between 5 and 6 cents, in a slow deflating trend from 9 cents a few months back.

NanoViricides, Inc. (OTCBB:NNVC) is another pharmaceutical company with promising drug plans, which is having an upward run, reaching $1.21 on medium-level trading. After the long weekend, NNVC will have to prove its mettle again.

If you need to adjust your exposure to the biotech sector, keep in mind that these tickers are prone to exuberant climbs, often followed by deep corrections, so stay away unless you are also able to absorb the corrections.

You may also like...